Sapreme Technologies develops an endosomal escape platform and compounds (notably SPT001) to improve delivery and efficacy of macromolecule therapeutics, including antibody-targeted antisense oligonucleotides (ASOs). The company applies this approach across its internal oncology pipeline and offers the platform for partnering across biologic modalities and indications. Preclinical data from 2020 and 2021 demonstrated SPT001's effectiveness, and recent in vivo data showed enhanced delivery of oligonucleotides to the liver using GalNAc targeting with strong gene knockdown at reduced doses. Following the Series A, Sapreme plans to mature and scale the platform, advance its proprietary pipeline, and expand collaborations with industry partners. Leadership is led by CEO Guy Hermans, Ph.D., and the company emphasizes further preclinical data generation to showcase its technology.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2021